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Epidemiological, phenotypic and genomic char-
acterisation of certain variants of SARS- CoV-2 
have highlighted the changing transmissibility, 
infectivity and antigenic escape capability of 
this virus. Of considerable interest are the 
B.1.1.7 variant (20I/501Y.V1)1 and B.1.351 
variant (20H/501Y.V2)2 that have now been 
reported from multiple countries around the 
world. B.1.1.7 was first detected in September 
2020 in the UK through genomic surveillance, 
and it contains a mutation (N501Y) in the 
receptor- binding domain of the spike protein 
that has been reported to increase transmis-
sion1 and virulence3 through genomic and 
epidemiological studies. The variant still shows 
strong response to antibody treatment and 
is effectively neutralised by antibodies gener-
ated on vaccination by mRNA- based vaccines.4 
The B.1.351, first identified in South Africa in 
October 2020,2 carries the N501Y mutation and 
two additional mutations (E484K and K471N) 
that confer increased antibody resistance.4 
These findings make it imperative to continu-
ously track circulating variants of SARS- CoV-2 
globally, especially in low- resource settings, to 
institute evidence- based policy decisions. This 
editorial aims to raise awareness regarding the 
increasing isolation of the B.1.1.7 and B.1.351 
variants and documented cases of re- infection 
in Bangladesh in recent months.
Bangladesh, one of the most densely popu-
lated countries of the world, detected the first 
SARS- CoV-2 cases on 8 March 2020. Immedi-
ately following that, non- pharmaceutical inter-
ventions including school closures, work from 
home mandate and flight bans were instituted 
for the following 2 months (figure 1A). After 
the first peak in July 2020 (3810 cases/day, 
7- day average) case numbers reduced, with a 
slight surge in December 2020 (2185 cases/day, 
7- day average) that also subsided.5 A small study 
conducted in July of 2020 estimated that sero-
prevalence in Dhaka, the capital of Bangladesh, 
ranged from 45% to 74%.6 However, starting in 
early March 2021, case numbers began to rise 
rapidly, and the reproduction number is esti-
mated to have doubled from 0.79 on 21 January 
2021 to 1.66 on 23 March 2021 (figure 1B). The 
average test positivity rate in the last week of 
March 2021 was 17% country- wide, when the 
average number of tests conducted was 26 127/
day.7 Bangladesh introduced the ChAdOx1 
(Oxford- AstraZeneca) vaccine on 27 January in 
2021, and as of 13 April 2021, 5.6 million people 
(of the 164 million population) have received 
the first dose of the vaccine, and 733 000 have 
received the second dose.7
Our group at the Child Health Research 
Foundation (CHRF) functions as a COVID-19 
testing and sequencing centre based in 
Dhaka, the capital of Bangladesh.8 From 
April 2020 through 30 March 2021, we have 
identified >12 000 cases in our testing facility, 
of which we have sequenced 204 SARS- CoV-2 
genomes. All PCR tests are conducted using 
the TaqPath COVID-19 Combo Kit (Thermo 
Fisher Scientific, A47814, Waltham, Massachu-
setts, USA), SARS- CoV-2 sequencing libraries 
are prepared using the ARTIC V.3 protocol, 
paired- end reads are generated using iSeq 100, 
and finally, consensus genomes are assembled 
using the IDSeq platform of the Chan Zuck-
erberg Initiative, as described elsewhere.9 
Samples are usually randomly selected from 
positive tests; in addition, we may sequence 
when case history suggests possible antigenic 
escape. Genomes with metadata are uploaded 
on GISAID.10 Additionally, we have developed 
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and regularly maintain a Bangladesh- specific build in 
Nextstrain11 of all SARS- CoV-2 isolates sequenced and 
uploaded to GISAID from entire Bangladesh.12
The monthly distribution of the Nextstrain clades 
of SARS- CoV-2 sequences from our testing facility are 
shown in figure 1C. Sequenced samples were randomly 
selected from positive cases with cycle threshold value 
<30, except six cases of possible re- infection or antigenic 
escape throughout the surveillance. The sequenced 
samples represented all eight administrative divisions 
of Bangladesh. We first detected the B.1.1.7 variant in 
December 2020 in our genomic surveillance. In the 
following 3 months of January, February and March 2021, 
21% (4/19), 16% (1/6) and 8% (3/36) of the genomes 
sequenced belonged to the B.1.1.7 lineage in our genomic 
surveillance (9 total). We identified B.1.351 variant in 
February 2021; in February and March, 33% (2/6) and 
77% (28/36) of the genomes sequenced belonged to 
the B.1.351 variant (30 total). The sequenced genomes 
are a small proportion of confirmed SARS- CoV-2 cases 
in the country, and hence may not reflect the diversity 
of SARS- CoV-2 circulating in Bangladesh. However, such 
genomic data collected over the entire period of the 
pandemic are overall scarce from South Asian countries; 
this surveillance provides us clues as to why cases may be 
rising in the entire region. In addition, new genomes 
being uploaded to GISAID by other groups in Bangla-
desh indicate a similar rise in variants. An additional 
100 sequences were uploaded on GISAID by two inde-
pendent groups in March 2021, where 72 belonged to 
B.1.351 (72%) and 10 to B.1.1.7 (10%).
TWO CASES OF SECOND INFECTION BY B.1.351 AND TWO 
CASES OF INFECTION AFTER VACCINATION USING ChAdOx1
All healthcare workers of CHRF are regularly screened 
for SARS- CoV-2 infection using RT- PCR. In March 2021, 
10 healthcare workers tested positive; samples from 
4 cases were sequenced as possible cases of antigenic 
escape, all of which were B.1.351, and whose details are 
provided below.
Cases of reinfection by B.1.351
Of the four cases of B.1.351 detected among CHRF 
healthcare workers, two were cases of reinfections. 
Throughout our genomic surveillance, we sequenced a 
total of three possible cases (six samples) of reinfection, 
one in July 2020, and two in March 2021; the latter two 
are described here. Case 1 (32 years old, female) was 
first confirmed to have an infection on 21 July 2020, with 
two consecutive positive tests over 7 days. Following reso-
lution of symptoms, there were 12 negative tests over 7 
months. On 21 March 2021 (routine screening), case 1 
tested positive again. Case 2 (28 years old, male) was first 
confirmed to have an infection on 23 June 2020, with 
three consecutive positive tests over 17 days. Following 
resolution of symptoms, there were 10 negative tests over 
8 months. On 21 March 2021 (routine screening), case 
2 tested positive again. Using genome sequencing, it was 
confirmed that in both cases, the first episode was caused 
by the Nextstrain clade 20A, and the second episode was 
by 20H/501Y.V2 (B.1.351). Neither of the cases received 
a vaccine. In both cases, the first and the second episodes 
were mild and did not require hospitalisation or any 
supplementary oxygen support.
Cases of infection after first dose of ChAdOx1
During this surveillance, two cases of infection by B.1.351 
were noted within the healthcare workers who received 
the first dose of ChAdOx1. We sequenced samples from 
both cases. Case 3 (24 years old, male) and case 4 (27 
years old, female) did not have any history of previous 
infection (either symptomatic or asymptomatic detected 
through regular screening) and received the first dose 
of ChAdOx1 on 14 and 16 February 2021, respectively. 
They both tested positive for SARS- CoV-2 B.1.351 during 
routine screening on 22 March 2021, 36 and 34 days after 
vaccination. Both cases were asymptomatic.
Figure 1 COVID-19 cases in Bangladesh and trends in 
circulating lineages of SARS- CoV-2. (A) The 7- day average of 
confirmed COVID-19 cases and deaths. (B) The reproductive 
rate (R0). Data for (A) and (B) were obtained from Our World 
in Data (https://ourworldindata.org/coronavirus). (C) The 
Nextstrain clades (Pangolin lineage) of the 204 SARS- CoV-2 
sequenced at the Child Health Research Foundation.
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CONCURRENT INCREASE OF VARIANT DETECTION AND CASES 
HAVE IMPORTANT IMPLICATIONS FOR VACCINE POLICIES
The isolation of these variants correlates to the rapid 
increase in the number of SARS- CoV-2 cases and test 
positivity rate in Bangladesh. Genomic surveillance must 
continue to monitor this trend as these findings have 
grave implications for mitigation and vaccination policies 
and must be considered by policy makers when designing 
public health interventions. We recommend re- introduc-
tion of strict non- pharmaceutical interventions to prevent 
further spread of these variants within Bangladesh and 
rise of new ones.
Recent evidence about the ChAdOx1 vaccine suggests 
that it provides limited protection against mild- moderate 
COVID-19 caused by the B.1.351 variant.13 However, 
concrete data on its efficacy in reducing severe disease 
is pending. This has led to questions about the circu-
lating variants in Bangladesh, decisions on ongoing and 
future vaccine policies, and whether ChAdOx1 can help 
mitigate the burden on hospital beds. Considering the 
resource- constrained health system of Bangladesh, any 
vaccine that provides protection, at least against the 
severe COVID-19 cases, will decrease the burden on 
the limited hospital and intensive care unit beds in the 
country. At the same time, introduction of updated or 
different vaccines may need to be considered as more 
data become available. This is particularly important for 
low- income and middle- income countries like Bangla-
desh that, unlike high- income countries, have had 
limited options for vaccine access to date. Data on effi-
cacy of ChAdOx1 on severe COVID-19 caused by the 
B.1.351 variant is urgently needed.
Patient public involvement
Research questions related to SARS- CoV-2 detection and 
sequencing were designed according to the public health 
needs of Bangladesh. COVID-19 test results are immedi-
ately confidentially shared with the Directorate General 
Health Services, Government of Bangladesh, who share 
them with the patients. Anonymised sequencing results 
are uploaded on online open- access platforms, GISAID 
and Nextstrain. Results of samples collected from CHRF 
healthcare works are shared with all participants in real 
time in Bangla and English.
Twitter Senjuti Saha @senjutisaha and Arif M Tanmoy @arif_tanmoy
Acknowledgements We thank the Directorate General Health Services, 
Government of Bangladesh, and the Institute of Epidemiology, Disease Control, 
and Research for giving us the opportunity to work as a COVID-19 response 
team. We thank all personnel at the Child Health Research Foundation involved 
in the COVID-19 diagnostic and clinical teamwork, and Sudipta Saha and Nazifa 
Tabassum for editorial assistance. We are very grateful to all healthcare workers 
of CHRF who regularly provided samples for testing and sequencing when needed, 
and our team members who facilitated sample collection, transport and storage. 
We are also grateful to the health facilities in Bangladesh that sent us samples 
for COVID-19 testing and sequencing, including Dr Ahmed Al Kabir, Dr Md. Parvej 
Alam and Md. Mobarok Karim of the Shimantik Pathology and Diagnostic Centre, 
Sylhet. We thank the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative and 
the Quadrum Institute for their intellectual support and guidance during genome 
sequencing.
Contributors SS: first draft preparation. SS, YH: visualisation. AMT, AAT, SG, 
MSIS, RM, SI, HR, NS: laboratory technique optimisation, data collection and 
quality assessment. YH, SMAS, AMA: data analysis. SS, AMT, HR, SKS, MSI, KG, 
PKS, MRAB, SSA, MS: overall management and administration. SS, SKS: funding, 
conceptualisation. All: manuscript finalisation.
Funding We received funding from the Bill and Melinda Gates Foundation (grants 
INV-016932, INV-023821) for this project.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval All protocols were approved by the National Research Ethics 
Committee, Bangladesh Medical Research Council and the ethical review board 
of the Bangladesh Institute of Child Health. Samples from suspected patients with 
COVID-19 are collected for clinical care and diagnostic testing at the discretion of the 
attending healthcare providers. Samples from CHRF healthcare workers for regular 
screening are taken on written consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access 
repository.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Senjuti Saha http:// orcid. org/ 0000- 0001- 6087- 6766
Arif M Tanmoy http:// orcid. org/ 0000- 0002- 7769- 8035
Yogesh Hooda http:// orcid. org/ 0000- 0002- 7181- 9254
Syed Muktadir Al Sium http:// orcid. org/ 0000- 0002- 9497- 5380
Samir K Saha http:// orcid. org/ 0000- 0003- 3820- 0748
REFERENCES
 1 Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS- 
CoV-2 lineage B.1.1.7 in England. Nature 2021. doi:10.1038/s41586-
021-03470-x. [Epub ahead of print: 25 Mar 2021].
 2 Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS- 
CoV-2 variant of concern in South Africa. Nature 2021;592:438–43.
 3 Davies NG, Jarvis CI, Edmunds WJ, et al. Increased mortality in 
community- tested cases of SARS- CoV-2 lineage B.1.1.7. Nature 
2021;34.
 4 Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine- elicited 
antibodies to SARS- CoV-2 and circulating variants. Nature 
2021;592:616–22.
 5 Roser M, Ritchie H, Ortiz- Ospina E. Coronavirus pandemic 
(COVID-19). Our World in data. Available: https:// ourworldindata. org/ 
coronavirus [Accessed 14 Apr 2021].
 6 The IEDCR and partners share insights on the prevalence, 
seroprevalence and genomic epidemiology of COVID-19 in Dhaka 
city. icddr,b - Press Releases. Available: https://www. icddrb. org/ 
quick- links/ press- releases? id= 97& task= view [Accessed 18 Apr 
2021].
 7 Coronavirus (COVID-19) update. Available: https:// dghs. gov. bd/ 
index. php/ en/ home/ 5343- covid- 19- update [Accessed 14 Apr 2021].
 8 Saha S, Malaker R, Sajib MSI, et al. Complete genome sequence 
of a novel coronavirus (SARS- CoV-2) isolate from Bangladesh. 
Microbiol Resour Announc 2020;9.
 9 Saha S, Ahmed ANU, Sarkar PK, et al. The direct and indirect impact 
of SARS- CoV-2 infections on neonates: a series of 26 cases in 
Bangladesh. Pediatr Infect Dis J 2020;39:e398–405.
 10 Elbe S, Buckland- Merrett G. Data, disease and diplomacy: GISAID's 
innovative contribution to global health. Glob Chall 2017;1:33–46.
 11 Hadfield J, Megill C, Bell SM, et al. Nextstrain: real- time tracking of 
pathogen evolution. Bioinformatics 2018;34:4121–3.
 12 Genomic epidemiology of novel coronavirus - Bangladesh- focused 
subsampling. Available: https:// nextstrain. org/ community/ CHRF- 
Genomics/ ncovBangladesh@ main [Accessed 14 Apr 2021].
 13 Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 
nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Eng J Med 
2021.












ealth: first published as 10.1136/bm
jgh-2021-006012 on 5 M
ay 2021. D
ow
nloaded from
 
